Focus: Olympus is a public medical device and imaging company headquartered in Pennsylvania with 201-500 employees, specializing in surgical products and diagnostic imaging across oncology, gastroenterology, and respiratory indications. The company operates as a mature player in the medical device space with a focus on minimally invasive and endoscopic solutions.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow Olympus to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Multiple trials active; core respiratory/minimally invasive device with repeated portfolio references indicating strategic importance.
Help build intelligence for Olympus
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Olympus's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Phase 2/3 stage in pulmonary disease; addresses high-prevalence chronic respiratory condition with minimally invasive delivery.
Foundational imaging platform with multiple active clinical studies demonstrating broad GI cancer detection applications.
Only Phase 3 pharmaceutical program (appears twice in pipeline); addressing large endocrinology/metabolic disease market.
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moRecent peer-reviewed publications with author affiliations at this company
Normalization is essential for accurate intraoperative perfusion assessment using near-infrared fluorescence imaging.
Ameliorating Effect of Continuous Treatment With an Amorphous Formula of Curcumin on Maternal Imidacloprid Exposure-Induced Suppression of Hippocampal Neurogenesis in Rats.
Showing 5 of 10 publications